PharmaDrug receives encouraging potency data for candidate DMT-analogue molecules designed to treat primary open angle glaucoma Terasaki Institute advances PharmaDrug’s candidate DMT-analogue molecules into next phase of potency/kinetics study Terasaki Institute initiates fabrication of novel medical device designed to deliver PharmaDrug’s lead candidate to glaucoma patients Toronto…


Previous articlePT296 – Dr. David Luke – Vital Psychedelic Conversations
Next articlePsychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?